Navigation Links
WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
Date:9/7/2007

NEW YORK, Sept. 7 /PRNewswire-FirstCall/ -- Richard Gabriel, Chief Executive Officer of DNAPrint Genomics, Inc. (OTC Bulletin Board: DNAG) (http://www.dnaprint.com) will be featured in an exclusive interview with http://www.wallst.net that is scheduled to take place on September 10 at 11 a.m. EDT. The interview will be posted on http://www.wallst.net by 8 p.m. EDT on September 10.

The interview will cover topics including DNAPrint Genomics' market potential, growth initiatives, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange at the top of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window on the right-hand column of the "Interviews" section.

About DNAPrint Genomics:

DNAPrint(TM) Genomics, Inc. is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for the treatment of anemia in renal dialysis patients (with end stage renal disease). DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests.

For more information about the company, please visit http://www.dnaprint.com.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com), a provider of media and compliance solutions to publicly traded companies. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com), a business and finance podcast Web site. Financial Filings Corp. is expecting to receive two hundred eighty dollars from DNAPrint Genomics, Inc. for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)

Contact: WallSt.net

800-4-WALL-ST


'/>"/>
SOURCE Financial Filings Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive results of ... in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a new small molecule drug ... National Institutes of Health. Continue Reading ... ... ...
(Date:3/27/2017)... -- The new research portal will give visitors ... on Valero Energy , offering extensive market research on ... ... http://photos.prnewswire.com/prnh/20160330/349511LOGO) The latest trend gaining momentum ... today, even though touted as a green alternative to fossil ...
(Date:3/27/2017)... 27, 2017  Trovagene, Inc. (NASDAQ: TROV), a precision ... Officer, Bill Welch , will be presenting at ... 9:00 AM EDT at the Essex House in ... Chief Scientific Officer, Mark Erlander , Ph.D., will ... conference.   The presentation will be webcast live ...
(Date:3/24/2017)... -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative ... and patent-protected processes to develop and market advanced products ...  that it will present at the Needham Healthcare Conference ... H. "Pete" Petit, Chairman and CEO, Michael J. ... , EVP and Chief Commercialization Officer, and Mark ...
Breaking Biology Technology:
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):